MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Personal Cancer Immunotherapy
    • The Clean Super Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Personal Cancer Immunotherapy
    • The Clean Super Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  

AIVITA Biomedical and University of California at Irvine Collaborators Validate 3D Printed Bioreactor for Retinal Organoid Creation

IRVINE, Calif. –  Jul. 13, 2021 – AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell…

AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

IRVINE, Calif. – June 8, 2021 – AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell…

AIVITA Biomedical CEO Hans Keirstead Receives 2021 Global Humanitarian Award

IRVINE, Calif. – March 04, 2021 – AIVITA Biomedical, a private biotechnology company developing personalized vaccines for the treatment…

AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19

IRVINE, Calif. – February 25, 2021 – AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the…

AIVITA Biomedical Closes $25 Million Financing Round

IRVINE, Calif. – December 29, 2020 – AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the…

AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

IRVINE, Calif. – Nov. 17, 2020 – AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell…

AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy

IRVINE, Calif. –  Nov. 2, 2020 – AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell…

AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science

IRVINE, Calif. –  October 9, 2020 – AIVITA Biomedical announced the publication of the peer-reviewed manuscript, “Retina organoid transplants…

AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management

IRVINE, Calif. –  August 3, 2020 – AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the…

AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research

IRVINE, Calif. – July 1, 2020 – AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the…

  • Previous
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target infectious diseases and tumor-initiating cells — the seed of all cancers — using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Licenses Novel Skincare Formulations to Global Skincare Retailer LevEllis
  • AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Join Keynote Panel for AI in Public Health at World Vaccine Congress
  • AIVITA Biomedical Strengthens Board of Directors with Appointment of Ex-Biogen CEO Michel Vounatsos
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Present at Biotech Showcase 2024

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2023 | AIVITA Biomedical, Inc.